Machsanei Hashuk Integrates WalkOut’s Smart-cart Solution in All Its Branches
9.12.2021 20:53:00 EET | Business Wire | Press release
The Israeli company WalkOut, the developer of an autonomous end-to-end frictionless shopping solution, announces an extensive cooperation agreement with Machsanei Hashuk, one of the largest supermarket chains in Israel. As part of the agreement, the chain will implement the fully autonomous checkout solution, considered the most accurate in the world's retail industry, in all 62 of its branches. Its deployment will begin as early as next month.
Although 61 percent of shoppers would prefer to purchase brands that also have a physical location, over 70 percent of shoppers report that standing in line for checkouts is frustrating and detracts from the shopping experience. Until the development of WalkOut’s solution, no system has accompanied the customer throughout the entire purchase, which includes actual checkout.
WalkOut’s retrofit smartcart solution offers a revolution in the shopping experience that addresses two main challenges that marketing chains face in the physical buying process.
The first is related to waiting in long queues at the checkout. The second is the inability to create a personalized shopping experience for each customer.
The company’s first-ever truly seamless retrofitted solution in the retail industry requires no costly infrastructural changes to the store, while other solutions require the retailer to purchase new carts and most rely on barcode scanners and scales for item recognition. The mountable cart device's multiple high-precision cameras, which utilize many different proprietary algorithms to accurately recognize products, identify the items as shoppers load or remove them with 99.2 percent accuracy.
WalkOut’s edge computing and machine-vision algorithms also curtail the need for costly on-cloud servers and high-bandwidth internet support. This use of single-sensor architecture and edge-computing allows retail stores to operate a much more robust and cost-effective solution. Through a large touchscreen, the device also communicates with the customer to offer personalized recommendations, store navigation, supplementary product information, and relevant promotions based on the shopper's history and location in the store.
"Connecting to one of the largest retail chains in Israel is an exciting opportunity and an important milestone for us," says Assaf Gedalia, CEO and Co-Founder of WalkOut. “The solution is futuristic, personalized, and at the same time preserves the customer's privacy."
"As a chain that advocates innovative technologies, we wanted to offer our customers significant savings in waiting times at the checkouts and provide a more personal, accessible and efficient shopping experience," said Shalom Naaman, CEO and Owner of Machsanei Hashuk. "The WalkOut solution will significantly shorten the length of stay in the branches, help maximize our operational efficiency, and allow us to offer one of the most advanced shopping experiences in the world."
About WalkOut
WalkOut, founded in 2018, has set itself the goal of changing the way consumers purchase products in physical stores by placing the checkout directly on the shopping cart. The company's solution is based on machine vision technology capable of identifying any item placed or removed from the cart and calculating it in the final payment. In this way, the cart eliminates the need for a checkout and reduces the duration of the payment process to a minimum. The WalkOut solution includes a large touch screen located on the cart and combines a personalized shopping experience with offers and promotions based on each consumer's preferences, complementary products and the location of the products in the store. The WalkOut system is modular and can be installed on existing carts in stores without the need for significant changes on the part of the store.
About Machsanei Hashuk
Machsanei Hashuk is a leading marketing chain owned and managed by the Naaman & Cohen families that was first established in 1996 in the city of Beer Sheva. The chain currently has 62 branches nationwide from Safed to Eilat. In 2019, the chain acquired Co-op, and in doing so became one of the largest leading marketing chains in Israel. Co-op branches have since been converted into "Machsanei Hashuk sheli''. The chain operates an advanced and accessible online site, in addition to its branches. It also offers its own Wincard+ credit card, in cooperation with Max, which combines regular card rewards with the chain's own promotions. Machsanei Hashuk operates a strong and active customer club with more than 400,000 loyal customers.
The chain is the official sponsor of the football team "Hapoel Machsanei Hashuk Beer-Sheva.” For more information, visit https://www.mck.co.il/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005892/en/
Contact information
Media Contact
Lea Berdugo
ReBlonde for WalkOut
lea@reblonde.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
